<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00829088</url>
  </required_header>
  <id_info>
    <org_study_id>D0475C00008</org_study_id>
    <secondary_id>EudractCT No: 2008-006129-14</secondary_id>
    <nct_id>NCT00829088</nct_id>
  </id_info>
  <brief_title>Investigation of Rate + Extent of Excretion of Radioactivity in Urine +Faeces After Oral Administration of [14C]AZD2066</brief_title>
  <official_title>An Open Label, Single Dose, Phase I Study of the Excretion of Radioactivity, Metabolism and Pharmacokinetics Following Oral Administration of [14C]AZD2066 to Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to get information about absorption, distribution, metabolism and
      excretion as well as the tolerability and safety of AZD2066 in healthy male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Excretion (rate and extent) of radioactivity in urine and faeces following oral administration of [14C]AZD2066</measure>
    <time_frame>Until &gt;90% of predicted total radioactivity has been recovered</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of total radioactivity in plasma and unchanged AZD2066 in plasma</measure>
    <time_frame>Sampling at defined timepoints during residential period from pre-dose until 168h post-dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolite profile in plasma and excreta</measure>
    <time_frame>Sampling at defined timepoints during residential period from pre-dose until 48h post-dose.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AZD2066 metabolites in plasma+excreta if feasable</measure>
    <time_frame>Sampling at defined timepoints during residential period from pre-dose until 48h post-dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of AZD2066 by assessment of vital signs, laboratory variables, ECG and adverse events</measure>
    <time_frame>Assessments taken at visit 1 (enrolment), defined time points pre dose and post dose during visit 2 (residential period) and follow up visit 3.</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">6</enrollment>
  <condition>Pain</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD2066</intervention_name>
    <description>1 dose oral solution</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of signed informed consent

          -  Clinically normal physical findings and laboratory values as judged by the
             investigator and a normal resting ECG.

        Exclusion Criteria:

          -  History of somatic disease/condition, which may interfere with the objectives of the
             study.

          -  History of previous or ongoing psychiatric disease/condition including psychosis,
             affective disorder, anxiety disorder, borderline state and personality disorder.

          -  Healthy volunteers who have been exposed to radiation levels above background (eg,
             through X-ray examinations).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emeline Ramos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AstraZeneca R&amp;D, CPU Alderley Park, UK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lars Ståhle, MD</last_name>
    <role>Study Chair</role>
    <affiliation>AstraZeneca R&amp;D, Södertälje, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cheshire</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2009</study_first_submitted>
  <study_first_submitted_qc>January 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2009</study_first_posted>
  <last_update_submitted>February 24, 2009</last_update_submitted>
  <last_update_submitted_qc>February 24, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2009</last_update_posted>
  <responsible_party>
    <name_title>Rolf Karlsten, MD, PhD, Medical Science Director, Emerging Analgesia, Neuroscience</name_title>
    <organization>AstraZeneca R&amp;D Södertälje, Sweden</organization>
  </responsible_party>
  <keyword>Mass balance</keyword>
  <keyword>AZD2066</keyword>
  <keyword>Pain</keyword>
  <keyword>Pain conditions</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

